# COMMANDS (NCT03682536)

> A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03682536
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Celgene
- Conditions: Myelodysplastic Syndromes
- Interventions: Luspatercept; Epoetin alfa
- Enrollment: 363
- Primary outcome: Percentage of Participants With Red Blood Cell Transfusion Independence (RBC-TI) for 12 Weeks (84 Days) With a Mean Hemoglobin Increase ≥ 1.5 g/dL

## Indexed commentary on COMMANDS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=commands-nct03682536